Uncommon Employee Directory
Biotechnology ResearchUnited Kingdom11-50 Employees
Uncommon Bio began with cell-based meat and pioneered RNA delivery innovations, which evolved into their most recent spin out which is focusing on changing medicine through multi-targeting. Their polysaccharide-based delivery platform enables multi-pathway cell programming, offering a safe, efficient and scalable alternative to multi-target therapies. The company is initially targeting severe lung diseases like idiopathic pulmonary fibrosis and is backed by industry leaders from BioNTech and top investors, including Sam Altman, Balderton, Lowercarbon, and Redalpine.